|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����20 |
|
��� |
| ��������������� | |
|
������ |
|
���� |
| PubMed | |
|
Article by ������ |
|
Article by ���� |
����20�����
������1, ����2
1. ����ʡ��������ҽԺƤ����, 221700;
2. ��ž�������ҽԺƤ����
����20��һ���·��ֵ�ϸ������,�ڽṹ�������10���и߶������,�������ѱ���¡.����20�����ɻ������Ѫ������ϸ���ͽ����γ�ϸ������,������м������֢���̲�������Ҫ����.
1. ����ʡ��������ҽԺƤ����, 221700;
2. ��ž�������ҽԺƤ����
1. ����ʡ��������ҽԺƤ����, 221700;
2. ��ž�������ҽԺƤ����
[2] Blumberg H, Conklin D, Xu WF, et al. Interleukin 20;discovery,receptor identification, and role in epidermal function. Cell, 2001,104(1):9-19.
[3] Cookson W. The alliance of genes and environment in asthma and allergy. Nature, 1999, 402(6760 Suppl):B5-11.
[4] Sano S, Itami S, Takeda K, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J, 1999, 18(17):4657-4668.
[5] O'Farrell AM, Liu Y, Moore KW, et al. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms;evidence for Stat3-dependent and-independent pathways. EMBO J, 1998, 17(4):1006-1018.
[6] Kunz M, Henseleit-Walter U, Sorg C, et al. Macrophage marker 27E10 on human keratinocytes helps to differentiate discoid lupus erythematosus and Jessner's lymphocytic infiltration of the skin. Eur J Dermatol, 1999, 9(2):107-110.
[7] Volk H, Asadullah K, Gallagher G, et al. IL-10 and its homologs:important immune mediators and emerging immunotherapeutic targets.Trends Immunol, 2001, 22(8):414-417.
[8] Gottlieb SL, Gilleaudeau P, Johnson R,et al. Response of psoriasis to a lymphocyte-selective toxin(DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med, 1995, 1(5):442-447.
[9] Carroll JM, Crompton T, Seery JP, et al. Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation,and hair loss. J Invest Dermatol,1997, 108(4):412-422.
[10] Mosmann TR. Properties and functions of interleukin-10. Adv Immunol, 1994, 56:1-26.
[11] Asadullah K, Docke WD, Sabat RV, et al. The treatment of psoriasis with IL-10;rationale and review of the first clinical trials. Expert Opin Investig Drugs, 2000, 9(1):95-102.
[12] Seiffert M, Sterry W, Effenberger E, et al. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes. Arch Dermatol Res, 2000, 292(4):164-172.